Patient access schemes for high-cost cancer medicines: Good in theory, difficult in practice
Sunday, January 31, 2010 - 18:49
in Mathematics & Economics
created by the pharmaceutical industry to allow access to expensive cancer drugs -can be fraught with administrative problems, meaning that money does not reach the parts of the UK National Health Service that it should, if at all. The issues are discussed in a Comment in the February edition of The Lancet Oncology, written by Steve Williamson, Northumbria Healthcare NHS Foundation Trust Pharmacy, North Tyneside Hospital, North Shields, UK.